(CercleFinance.com) – The NFL Biosciences title is up Monday on the Paris Stock Exchange, driven by an initiation of purchase hedging from Invest Securities analysts.
At 11:15 am, the stock rose 1.4%, while the CAC Mid & Small index advanced 0.2%.
Invest began this morning to purchase its value hedge with a price target of 4.9 euros, or upside potential of 36%, welcoming an ‘innovative’ approach against addiction
« We appreciate the group’s positioning in the treatment of addiction (tobacco / cannabis / alcohol) with a pipeline of three botanical drugs », explains the Parisian research office.
Regarding the main product, NFL-101, entered phase II / III in the treatment of tobacco addiction with results expected at the end of 2023, Invest says it expects a commercial launch in 2026 for a sales peak of 900 million. euros.
Since its IPO on July 5, the title NFL Biosciences has shown a relatively stable course, the biopharmaceutical company having been introduced at a price of 3.8 euros.
Copyright (c) 2021 CercleFinance.com. All rights reserved.